Table 4. Univariate and multivariate analyses of different pre-therapeutic parameters and their impact on overall survival (only the significant parameters are shown).
| Parameters | p-value | Median OS reported in weeks (95 % CI) | Multivariate analysis p-value |
|---|---|---|---|
| Number of bone metastases 29 patients ≤ 20 met 45 patients > 20 met 24 patients : super scan or diffuse bone/bone marrow met |
0.02 | 94 (60.7–127.3) 55 (38.8–71.2) 37 (12.7–61.3) |
ns |
| Existence of liver metastases 13 patients: yes 87 patients: no |
0.04 | 28 (18.6–37.4) 60 (47.3–72.7) |
0.02 HR: 3.2 (95% CI: 1.5–7.1) |
| ECOG performance status (0/1 vs 2/3) 77patients: 0–1 23 patients: 2–3 |
< 0.0001 | 71 (43.7–98.3) 33 (24.7–41.3) |
ns |
| Blood transfusion prior to the first cycle 16 patients: yes 84 patients: no |
0.04 | 36 (28.3–43.7) 63 (49.5–76.5) |
ns |
| Albumin (cut-off: 38.6 g/l) 49 patients ≤ 38.6 51 patients > 38.6 |
0.0003 | 38 (26.0–50.0) 95 (47.3–142.7) |
0.01 HR: 0.9 (95% CI: 0.8 – 0.95) |
| AST (cut-off: 24 U/l)) 56 patients ≤ 24 44 patients > 24 |
0.0002 | 88 (61.1–114.9) 36 (16.8–55.2) |
0.04 HR: 2.5 (95% CI: 1.3 –4.8) |
| GGT (cut-off: 31 U/l) 42 patients ≤ 31 58 patients > 31 |
0.0001 | 88 (63.4–112.6) 47 (31.5–62.5) |
ns |
| ALP (cut-off: 140 U/l) 52 patients ≤ 140 48 patients > 140 |
0.0003 | 71 (45.9–96.0) 42 (24.0–60.0) |
ns |
| ALP (cut-off: 220 U/l) 65 patients ≤ 220 35 patients > 220 |
0.019 | 70 (56.9–83.1) 37 (17.7–56.2) |
ns |
| LDH (cut-off: 225 U/l) 36 patients < 225 64 patients ≥ 225 |
< 0.0001 | not reached 46 (29.6–62.4) |
ns |
| Hb (cut-off: 10.4 g/dl) 33 patients <10.4 67 patients ≥10.4 |
0.0001 | 36 (24.5–47.5) 88 (60.7–115.3) |
< 0.0001 HR: 0.5 (95% CI: 0.2–0.9) |
| CRP (cut-off: 16 mg/l) 65 patients ≤ 16 35 patients > 16 |
0.0001 | 71 (46.8–95.2) 33 (25.2–40.8) |
ns |
| Regular need for analgesics 39 patients: yes 61 patients: no |
0.007 | 36 (24.7–47.3) 70 (56.1–83.9) |
ns |
| Regular need for opioids 35 patients: yes 65 patients: no |
0.0002 | 33 ( 24.9–41.1) 88 (48.0–127.9) |
ns |
| PSA percent change (cut-off: –14%) 62 patients: decline > 14 % 38: no PSA decline or decline ≤ 14% |
< 0.0001 | 88 (58.3–117.7) 29 (20.1–37.8) |
< 0.0001 HR: 6.9 (95% CI: 3.6 - 13.3) |
| PSA any decline 69 patients: yes 31 patients: no |
< 0.0001 | 71 (45.4–96.6) 29 (20.5–37.5) |
ns |
| PSA decline ≥ 50% 38 patients: yes 62 patients: no |
0.009 | 70 (39.5–100.5) 49 (30.2–67.8) |
ns |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; Hb, haemoglobin; HR, hazard ratio; LDH, lactate dehydrogenase; ns, not significant; Plt, platelets; PSA, prostate-specific antigen; WBC, white blood cells.